Respiratory syncytial virus infections in infants and children with congenital heart disease: Update on the evidence of prevention with palivizumab

Current Opinion in Cardiology

Volumn 28, Issue 2, 2013, Pages 85-91

  Resch, Bernhard ^a   Michel Behnke, Ina ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

congenital heart disease; palivizumab; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTIFICIAL VENTILATION; CARDIOPULMONARY BYPASS; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEART SURGERY; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; IMMUNOPROPHYLAXIS; INFANT DISEASE; INFECTION PREVENTION; MORTALITY; PATIENT COMPLIANCE; PATIENT SELECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COMORBIDITY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEART DEFECTS, CONGENITAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 84873431168     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835dce2f     Document Type: Review

References (54)

1. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307:397-400.
2. Moler FW, Khan AS, Meliones JN, et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: A recent experience. Crit Care Med 1992; 20:1406-1413.
3. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992; 121:348-354.
4. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995; 126:212-219.
5. Simoes EA, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998; 133:492-499.
6. Feltes TF, Cabalka AK, Meissner HC, et al., Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-540.
7. Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009; 94:785-789.
8. Kristensen K, Hjuler T, Ravn H, et al. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: A population-based cohort study. Clin Infect Dis 2012; 54:810-817.
9. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects - hospitalizations and costs. Acta Paediatr 2006; 95:404-406.
10. Simon A, Müller A, Khurana K, et al. Nosocomial infection: A risk factor for a complicated course in children with respiratory syncytial virus infection -results from a prospective multicenter German surveillance study. Int J Hyg Environ Health 2008; 211:241-250.
11. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, et al. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004; 89:961-965.
12. Hervá s D, Reina J, Yanez A, et al. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis 2012; 31:1975-1981.
13. Medrano C, Garcia-Guereta L, Grueso J, et al. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: The CIVIC Epidemiologic Study. Cardiol Young 2007; 17:360-371.
14. Simon A, Ammann RA, Wilkesmann A, et al., DSM RSV Paed Study Group. Respiratory syncytial virus infection in 406 hospitalized premature infants: Results from a prospective German multicentre database. Eur J Pediatr 2007; 166:1273-1283.
15. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329:1524-1530.
16. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
17. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: A contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000; 21:433-438.
18. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 1999; 27:1974-1981.
19. Thorburn K. Preexisting disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009; 94:99-103.
20. Jung JW. Respiratory syncytial virus infection in children with congenital heart disease: Global data and interim results of Korean RSV-CHD survey. Korean J Pediatr 2011; 54:192-196.
21. Hon KL, Leung TF, Cheng WY, et al. Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis. J Crit Care 2012; 27:464-468.
22. Lanari M, Rossi GA, Merolla R, di Luzio Paparatti U. High risk of nosocomialacquired RSV infection in children with congenital heart disease. J Pediatr 2004; 145:140.
23. Linde LM, Siegel SI, Martelle RR, Simmons DH. Lung function in congenital heart disease. Dis Chest 1964; 46:46-50.
24. Sulc J, Andrle V, Hruda J, et al. Pulmonary function in children with atrial septal defect before and after heart surgery. Heart 1998; 80:484-488.
25. Pianosi PT, Johnson JN, Turchetta A, Johnson BD. Pulmonary function and ventilatory limitation to exercise in congenital heart disease. Congenit Heart Dis 2009; 4:2-11.
26. Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004; 23 (1 Suppl.):S41-S45.
27. Cohen SA, Zanni R, Cohen A, et al., Palivizumab Outcomes Registry Group. Palivizumab use in subjects with congenital heart disease: Results from the 2002-2004 Palivizumab Outcomes Registry. Pediatr Cardiol 2008; 29:382-387.
28. Saji T, Nakazawa M, Harada K. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease. Pediatr Infect Dis J 2008; 27:1108-1109.
29. Parnes C, Guillermin J, Habersang R, et al., Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35:484-489.
30. Golombek SG, Berning F, Lagamma EF. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 2004; 23:318-322.
31. Resch B, Gusenleitner W, Müller W, Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis 2006; 25:120-122.
32. Fenton C, Scott LJ, Plosker GL. Palivizumab: A review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs 2004; 6:177-197.
33. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124:1694-1701.
34. Tulloh R, Marsh M, Blackburn M, et al. Working Group of the British Paediatric Cardiac Association. Cardiol Young 2003; 13:420-423.
35. Geskey JM, Thomas NJ, Brummel GL. Palivizumab in congenital heart disease: Should international guidelines be revised? Expert Opin Biol Ther 2007; 7:1615-1620.
36. Nakazawa M, Saji T, Ichida F, et al. Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr Int 2006; 48:190-193.
37. Chantepie A; bureau de la Filiale de Cardiologie Pé diatrique de la Socié té Française de Cardiologie. Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society. Arch Pediatr 2004; 11:1402-1405.
38. National Advisory Committee on Immunization (NACI). Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab) Can Commun Dis Rep 2003; 29:1-15.
39. Schmaltz AA. Statement of the German Society of Paediatric Cardiology regarding RSV prophylaxis with Palivizumab (Synagis1) [in German]. Monatsschr Kinderheilkd 2004; 152:222-223.
40. Pinter M, Geiger R. Recommendations for RSV immune prophylaxis in infants and children with congenital heart disease [in German]. Monatsschr Kinderheilkd 2005; 153:878-880.
41. Swiss Society of Paediatrics. Paediatrica 2004; 16:14-16. www.swisspaediatrics. org/paediatrica/vol15/n6/pdf/14-16.pdf. [Accessed 27 December 2012]
42. Warren A, Langley JM, Thomas W, Scott J. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: A successful provincial respiratory syncytial virus prophylaxis program. Can J Cardiol 2007; 23:463-466.
43. Yount LE, Mahle WI. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004; 114:1606-1611.
44. Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005; 15:251-255.
45. Feltes TF, Simoes E. Palivizumab prophylaxis in haemodynamically significant congenital heart disease. Arch Dis Child 2005; 90:875-879.
46. Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007; 7:1471-1480.
47. Nuijyten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ 2009; 12:301-308.
48. Chang RK, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol 2010; 31:90-95.
49. Harris KC, Anis AH, Crosby MC, et al. Economic evaluation of palivizumab in children with congenital heart disease: A Canadian perspective. Can J Cardiol 2011; 27:e11-e15.
50. Kim NK, Choi JY. Respiratory syncytial virus prevention in children with congenital heart disease: who and how? Korean J Pediatr 2011; 54:197-200.
51. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: Systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011; 15:iiiYiv, 1-124. doi:10.3310/hta15050.
52. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis. Clin Ther 2000; 22:1357-1369.
53. Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res 2008; 8:529-538.
54. Resch B, Sommer C, Nuijten MJ, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 2012; 31:e1-e8.